San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug sector in February soon after revealing promising data from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection As well as in March t